click enter text
mix bag pki revis guidanc ep high end lower
tax cost cut sale lower full year impli organ
deceler unwind signal earli outlook put
previou guidanc hsd organ growth paus driver
chang includ slower macro/fund appli market slow ramp
vanadi transit lab busi drive tender refus
cost revenu quarter outlook emb
conservat applied/industri demand spite encourag durabl
china all-told pki outlook get closer base case
concern larg resolv price target increas modestli
cost cut lower tax rate benefit ep offset lower revenu
estim chang nomin post cut made tool
observ quarter da encouragingli still track
msd easier comp service/environmental/pharma hold
genom lab migrat branford pittsburgh
drag diagnost persist earli hsd revenu
growth guidanc reiter appropri reflect appli market
trend lab migrat updat vanadi strategi open door
broader reproduct genet kit strategi market china
growth held steadi msd ep guidanc goe high end lower
tax rate oper leverag exhibit margin track well ahead
plan ebit revenu miss off-set lower
opex cost-out effort includ restructur tax rate also ad
ep exhibit
digest competit announc acquisit meizheng
group food safeti test compani china sale
busi consum reagent grow top line
model return cash year four meizheng broad array
regulatori approv includ molecular across full breadth food
wolf research pleas announc inaugur healthcar confer ny
novemb click regist view agenda
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
exhibit varianc vs wr consensu
page
vs ep impactcon estimate vs con org bpsdiscoveri org bp total growth bp fx bpsacq divest purchas acct adj bp organ adj gross total oper incom interest incom incom dilut share gross bp oper bpseffect tax bp net price-to-earnings premium tool median median medianebit margin chang chang ebit margin
guidanc updat wolf model chang
exhibit chang forecast
page
annualest guidanc non-gaaprevenu ebit margin interest epsquarterlywolfeguid non-gaaprevenu sg tax perkinelm
page
excl -euroimmun/vanadis/genet organ adj blood ex-euroimmun/vanadis/genet ex-euroimmun/vanadis/gx organ growthyoy growthstackedforecast
page
page
yieldfcf compound-annual-growth-rate ebitda compound-annual-growth-rate ev-ebitda vs estimate ebitda compound-annual-growth-rate tool ntm price-to-earnings ratio median price-to-earnings premium compound-annual-growth-rate
note figur million unless state per-shar term
page
note figur million unless state per-shar term
page
report growth
note figur million unless state per-shar term
page
debt excess par deficit comprehens debt cash per debt day day convers
note figur million unless state per-shar term
page
op asset sale continu op debt issuanc cost acq inventori revalu assets/li total cont op dc op oper continu op dc op issuanc conting comp grant tax benefit grant proce cont op dc op financ fx net cash equival begin per per share share
